FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis Phase 2b refractory chronic cough trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results